Bodycote (LSE:BOY) has published the scheme document for its board-backed cash Acquisition by Vulcan Alpha Bidco, a company owned by funds managed by Veritas Capital, and the Shareholder meetings are set for 21 October 2026. Separately, rival suitor CVC has said it does not intend to make an offer.

What was announced

Bodycote plc (LSE:BOY) announced on 28 September 2026 that it had published the scheme document for the board-backed cash acquisition by Vulcan Alpha Bidco Limited. BidCo is indirectly wholly owned by funds managed by Veritas Capital Fund Management. The deal is being carried out through a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006. It follows a firm offer announcement under Rule 2.7 of the Takeover Code made jointly by the two companies on 1 September 2026.

On the same day, CVC Advisers Limited made a statement under Rule 2.8 of the Takeover Code. It confirmed that "it does not intend to make an offer to acquire Bodycote."

The offer terms

The 28 September announcement did not restate the price. According to the 1 September Rule 2.7 announcement, Bodycote shareholders will receive 932.8p in cash for each share. They will also keep the FY26 Interim Dividend of 7.2p per share, bringing the total value to 940p per share. That announcement valued Bodycote's fully diluted Share Capital at about £1,640m and gave an Enterprise value of about £1,840m. It said the price was a 37.5% premium to the three-month volume-weighted average price of 683.4p to 21 May 2026, and a 25.3% premium to the closing price of 750.2p on 4 August 2026.

The Rule 2.7 announcement also said CVC had put forward a competing proposal of 915p per share, including the dividend, but had not announced a firm intention to make an offer.

Meetings and timetable

The Court Meeting will be held at 10.00am on 21 October 2026, followed by the General Meeting at 10.15am, or as soon as the Court Meeting ends. Both will take place at the Hilton London Paddington, 146 Praed Street, London W2 1EE. The deadlines for proxy forms are 10.00am on 19 October 2026 for the Court Meeting (blue form) and 10.15am on 19 October 2026 for the General Meeting (yellow form).

At the Court Meeting, the scheme must be approved by a majority in number of the scheme shareholders who vote, representing at least 75% in value of the shares voted. At the General Meeting, the special resolution needs the required majority. After that, the Court must sanction the scheme, and regulatory conditions set out in the scheme document must also be met.

Bodycote expects the Court sanction hearing to take place on 11 March 2027. The scheme is expected to become effective, and the shares to be delisted, in the first quarter of 2027. The long stop date is 1 September 2027. These dates are indicative.

The Bodycote directors unanimously support the scheme and are asking shareholders to vote in favour. Directors holding 252,480 shares, about 0.15% of the issued share capital according to the Rule 2.7 announcement, have given irrevocable undertakings to vote in favour.

CVC's statement and what to watch next

Having made its statement, CVC is bound by Rule 2.8 for six months. It has reserved the right to set aside that restriction in certain cases: with the agreement of the Bodycote board, or if the Vulcan offer is withdrawn or lapses; if a third party announces a firm intention to make an offer; if Bodycote announces a Rule 9 Waiver proposal or a reverse takeover; or if the Takeover Panel decides there has been a material change of circumstances. CVC thanked the Bodycote board and management for their "constructive engagement".

Next come the 21 October meetings, then regulatory approvals and Court sanction.